Last reviewed · How we verify
MOB015B
MOB015B is a topical antimicrobial agent designed to treat fungal nail infections by inhibiting fungal growth and promoting nail clearance.
MOB015B is a topical antimicrobial agent designed to treat fungal nail infections by inhibiting fungal growth and promoting nail clearance. Used for Onychomycosis (fungal nail infection).
At a glance
| Generic name | MOB015B |
|---|---|
| Sponsor | Moberg Pharma AB |
| Drug class | Topical antifungal |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
MOB015B is a nail lacquer formulation developed for onychomycosis (fungal nail infection) treatment. The drug works by delivering antifungal activity directly to infected nail tissue, with the goal of improving nail penetration and efficacy compared to existing topical treatments. It is being evaluated in phase 3 clinical trials for moderate-to-severe toenail onychomycosis.
Approved indications
- Onychomycosis (fungal nail infection)
Common side effects
- Application site irritation
- Nail discoloration
- Contact dermatitis
Key clinical trials
- A Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO) (PHASE3)
- Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design (PHASE1)
- Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design (PHASE1)
- A Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO) (PHASE3)
- Study to Evaluate the Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO) (PHASE3)
- A Study of the Systemic Absorption of MOB015B (PHASE1)
- An Open,Single-centre Pilot Study of Efficacy and Safety of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MOB015B CI brief — competitive landscape report
- MOB015B updates RSS · CI watch RSS
- Moberg Pharma AB portfolio CI